Morgan Stanley’s Enliven Therapeutics ELVN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$20.3M Buy
518,572
+106,749
+26% +$2.96M ﹤0.01% 2948
2025
Q4
$6.34M Buy
411,823
+153,439
+59% +$3.06M ﹤0.01% 3999
2025
Q3
$5.29M Buy
258,384
+3,536
+1% +$71.3K ﹤0.01% 4104
2025
Q2
$5.11M Buy
254,848
+173,533
+213% +$3.29M ﹤0.01% 4047
2025
Q1
$1.6M Sell
81,315
-29,291
-26% -$630K ﹤0.01% 4746
2024
Q4
$2.49M Sell
110,606
-24,801
-18% -$643K ﹤0.01% 4558
2024
Q3
$3.46M Buy
135,407
+67,107
+98% +$1.55M ﹤0.01% 4245
2024
Q2
$1.6M Buy
68,300
+5,203
+8% +$110K ﹤0.01% 4690
2024
Q1
$1.11M Sell
63,097
-95,945
-60% -$1.47M ﹤0.01% 4900
2023
Q4
$2.2M Buy
159,042
+125,072
+368% +$1.53M ﹤0.01% 4872
2023
Q3
$464K Buy
33,970
+649
+2% +$10.9K ﹤0.01% 5199
2023
Q2
$680K Buy
33,321
+15,903
+91% +$321K ﹤0.01% 5053
2023
Q1
$381K Buy
17,418
+3,231
+23% +$65.7K ﹤0.01% 5407
2022
Q4
$232K Sell
14,187
-1,129
-7% -$18K ﹤0.01% 5604
2022
Q3
$140K Sell
15,316
-7,708
-33% -$45.5K ﹤0.01% 5904
2022
Q2
$112K Sell
23,024
-2,460
-10% -$12K ﹤0.01% 6213
2022
Q1
$191K Sell
25,484
-57,211
-69% -$377K ﹤0.01% 5948
2021
Q4
$744K Buy
82,695
+10,033
+14% +$132K ﹤0.01% 5288
2021
Q3
$1.19M Sell
72,662
-34,596
-32% -$719K ﹤0.01% 4943
2021
Q2
$3.39M Buy
107,258
+26,676
+33% +$827K ﹤0.01% 4172
2021
Q1
$2.72M Buy
80,582
+78,531
+3,829% +$3.99M ﹤0.01% 4010
2020
Q4
$181K Buy
2,051
+1,815
+769% +$152K ﹤0.01% 5642
2020
Q3
$19K Sell
236
-1,006
-81% -$90.7K ﹤0.01% 6087
2020
Q2
$136K Sell
1,242
-34,847
-97% -$3.9M ﹤0.01% 5250
2020
Q1
$2.31M Buy
+36,089
New +$2.3M ﹤0.01% 3236

Other funds holding ELVN